Role of opiates and their receptors in the regulation of food intake and body weight

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 2, 2005, Pages 171-175

  Hadcock, John R ^a   Scott, Dennis O ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; ANTIOBESITY AGENT; BETA FUNALTREXAMINE; BIOLOGICAL MARKER; BUTORPHANOL; FENTANYL; FLUOXETINE; LY 255582; METHADONE; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; SPIRADOLINE; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DISEASE MODEL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; EATING DISORDER; ENERGY BALANCE; FOOD INTAKE; HUMAN; NONHUMAN; OBESITY; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; WEIGHT REDUCTION;

EID: 22144450660     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.05.011     Document Type: Review

References (32)

1. A.A. Hedley et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002 JAMA 291 2004 2847-2850
2. M. Waldhoer et al. Opiate receptors Annu. Rev. Biochem. 73 2004 953-990
3. J. Hughes et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity Nature 258 1975 577-580
4. Gutstein, H.B. and Akil, H. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th edn), pp. 569-619, Chapter 23
5. M.J. Barnes et al. High fat feeding is associated with increased blood pressure, sympathetic nerve activity and hypothalamic mu opioid receptors Brain Res. Bull. 61 2003 511-519
6. D. Giugliano and P.J. Lefebvre A role for beta-endorphin in the pathogenesis of human obesity? Horm. Metab. Res. 23 1991 251-256
7. W.R. Martin et al. Tolerance to and physical dependence on morphine in rats Psychopharmacologia 4 1963 247-260
8. J.E. Morley et al. Effect of butorphanol tartrate on food and water consumption in humans Am. J. Clin. Nutr. 42 1985 1175-1178
9. Tallman et al. Effect of chronic methadone use in humans on taste and dietary preference Federation Proc. 43 1984 1058 (abstract)
10. J.M. Rudski et al. Effects of methadone on free feeding in satiated rats Pharmacol. Biochem. Behav. 43 1992 1033-1037
11. S.G. Holtzman Behavioral effects of separate and combined administration of naloxone and D-amphetamine J. Pharmacol. Exp. Ther. 189 1973 51-60
12. J.L. Cole et al. Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats Brain Res. 678 1995 168-176
13. J.L. Cole et al. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese Zucker rats Peptides 18 1997 1201-1207
14. J.L. Cole et al. Dietary history affects the potency of chronic opioid receptor antagonist effects upon body weight in rats Nutr. Neurosci. 1 1999 405-417
15. M.R. Yeomans and R.W. Gray Opioid peptides and the control of human ingestive behavior Neurosci. Behav. Rev. 26 2002 713-728
16. M.A. Statnick et al. Peptides that regulate food intake: Antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization Am. J. Physiol. Regul. Integr. Comp. Physiol. 84 2003 1399-1408
17. C.H. Mitch et al. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: Opioid antagonists with potent anorectant activity J. Med. Chem. 36 1993 2842-2850
18. W.N. Shaw Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants Pharmacol. Biochem. Behav. 46 1993 653-659
19. R.Z. Chen et al. Chronic administration of nalmefene leads to increased food intake and body weight gain in mice Eur. J. Pharmacol. 495 2004 63-66
20. P.J. Emmerson et al. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists Eur. J. Pharmacol. 494 2004 121-130
21. R. Malcolm et al. A controlled clinical trial of naltrexone in obese humans Int. J. Obesity 9 1985 347-353
22. J.E. Mitchell et al. High-dose naltrexone therapy and dietary counseling for obesity Biol. Psych. 22 1987 35-42
23. F. Fruzzetti et al. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome Fertil. Steril. 77 2002 936-944
24. M. Guido et al. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome J. Clin. Endocr. Metab. 83 1998 1742-1745
25. R.L. Atkinson et al. Effects of long-term therapy with naltrexone on body weight in obesity Clin. Pharm. Ther. 38 1985 419-422
26. I. Raingeard e al. Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders Diabetes Care 27 2004 847-848
27. C.A. Maggio et al. Naltrexone and human eating behavior: A dose ranging inpatient trial in moderately obese men Brain Res. Bull. 14 1985 657-661
28. R.F. Novi et al. The role of opioid antagonists in the treatment of obesity. Results of a clinical trial with naltrexone Minerva Endocrinol. 15 1990 121-123
29. A. Ferrari et al. Serum time course of naltrexone and 6-beta-naltrexol levels during long term treatment in drug addicts Drug Alcohol Depend. 52 1998 211-220
30. J. Froehlich et al. Preclinical and clinical studies on naltrexone: What have they taught each other? Alcohol. Clin. Exp. Res. 27 2003 533-539
31. S.J. Porter et al. In vivo and in vitro potency studies of 6-beta-naltrexol, the major human metabolite of naltrexone Addict. Biol. 7 2002 219-225
32. R.M. Rodgers et al. Metabolism and choleretic effect of naltrexone in the isolated perfused rat liver Drug Metab. Dispos. 8 1980 390-396